Amylyx Pharmaceuticals, Inc. (AMLX) vs Supernus Pharmaceuticals, Inc. (SUPN)
- Amylyx Pharmaceuticals, Inc. AMLX 26.34 −4.74%
- Supernus Pharmaceuticals, Inc. SUPN 37.88 −4.27%
Amylyx Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.3B — 1.5× the size. Supernus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 24.9% against −77.1%. Amylyx Pharmaceuticals, Inc. has the higher net margin (0.00% vs −13.2%) and the higher return on invested capital (0.00% vs −12.4%). Across the 16 metrics below, Supernus Pharmaceuticals, Inc. leads on 11 and Amylyx Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | AMLX | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 88.07% | 53.94% |
| Operating margin | 0.00% | (15.71%) | 0.00% |
| Net margin | 0.00% | (13.23%) | 0.00% |
| Free cash flow margin | 0.00% | 2.21% | 0.00% |
| Return on equity | (74.73%) | (10.49%) | (0.40%) |
| Return on assets | (66.25%) | (7.82%) | (3.32%) |
| Return on invested capital | 0.00% | (12.37%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack